22CM
TEVA icon

20/20 Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

20/20 Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34
Closed – – 175
2020
Q3 		$0 Hold
34
– – ﹤0.01% 158
2020
Q2 		$0 Hold
34
– – ﹤0.01% 157
2020
Q1 		$0 Buy
+34
New +$348 ﹤0.01% 153

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

20/20 Capital Management's TEVA Position: Q4 2020 in Review

20/20 Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 34 shares.

20/20 Capital Management first reported a position in TEVA in Q1 2020 and held it in 3 quarters. The position peaked at $0 in Q3 2020. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

  • 20/20 Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • 20/20 Capital Management sold 34 Teva Pharmaceuticals shares in Q4 2020.
  • 20/20 Capital Management first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • 20/20 Capital Management's Teva Pharmaceuticals position peaked at $0 in Q3 2020.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on 20/20 Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.